Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)

被引：0
|
作者：
Majid, Oneeb [1 ]
Xiao, Jianjun Alan [2 ]
Sahmoud, Tarek [2 ]
Yasuda, Sanae [3 ]
Cantagallo, Lisa [2 ]
Hamilton, Erika P. [4 ]
Pluard, Timothy [5 ]
Juric, Dejan [6 ]
Gualberto, Antonio [2 ]
Husseiin, Ziad [1 ]
机构：
[1] Eisai, Hatfield, Herts, England
[2] H3 Biomed, Cambridge, MA USA
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] St Lukes Canc Inst, Kansas City, MO USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS12-15
引用
收藏
页数：1
相关论文
共 50 条
  • [11] ESTROGEN RECEPTOR AS A NEGATIVE PREDICTOR OF COMPLETE PATHOLOGICAL RESPONSE IN HER2 POSITIVE LOCALLY ADVANCED BREAST CANCER
    Canario, Rita
    Cruz, Jorge
    Casalta-Lopes, Joao
    Goncalves, Bruno
    Mariano, Monica
    Broco, Sofia
    Pais, Ana
    Pazos, Isabel
    Carvalho, Teresa
    Pego, Antonio
    Madeira, Pedro
    Sousa, Gabriela
    Gervasio, Helena
    BREAST, 2015, 24 : S46 - S46
  • [12] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [13] Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
    Hamilton, Erika P.
    Wang, Judy S.
    Pluard, Timothy
    Johnston, Stephen
    Morikawa, Aki Aki
    Dees, Claire E.
    Jones, Robert H.
    Haley, Barbara
    Armstrong, Anne
    Cohen, Adam L.
    Munster, Pamela
    Wright, Gail
    Kayali, Fadi
    Korpal, Manav
    Yu, Lihua
    Cantagallo, Lisa
    Destenaves, Benoit
    Zhang, Zhaojie
    Gao, Lei
    Pipas, Marc J.
    Sahmouud, Tarek
    Gualberto, Antonio
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
  • [14] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara
    Loibl, Sibylle
    Tolaney, Sara
    Kaklamani, Virginia
    Tonini, Giulia
    Matheny, Shannon
    Theall, Kathy Puvana
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [15] Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)
    Hamilton, E.
    Vidula, N.
    Ma, C.
    LoRusso, P.
    Bagley, R. G.
    Yu, Z.
    Annett, M.
    Weitzman, A.
    Conlan, M. G.
    Weise, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [16] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [17] Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
    Hamilton, Erika P.
    Wang, Judy S.
    Pluard, Timothy J.
    Johnston, Stephen R. D.
    Morikawa, Aki
    Dees, Elizabeth Claire
    Jones, Robert Hugh
    Haley, Barbara B.
    Armstrong, Anne Caroline
    Cohen, Adam Louis
    Munster, Pamela N.
    Wright, Gail Lynn Shaw
    Kayali, Fadi
    Korpal, Manav
    Xiao, Jianjun Alan
    Long, Jenny
    Destenaves, Benoit
    Gao, Lei
    Gualberto, Antonio
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [18] Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
    Utthara Nayar
    Ofir Cohen
    Christian Kapstad
    Michael S. Cuoco
    Adrienne G. Waks
    Seth A. Wander
    Corrie Painter
    Samuel Freeman
    Nicole S. Persky
    Lori Marini
    Karla Helvie
    Nelly Oliver
    Orit Rozenblatt-Rosen
    Cynthia X. Ma
    Aviv Regev
    Eric P. Winer
    Nancy U. Lin
    Nikhil Wagle
    Nature Genetics, 2019, 51 : 207 - 216
  • [19] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [20] Estrogen receptor (ER) status and survival outcomes in HER2 positive (+) metastatic breast cancer (mBC).
    DeSouza, Karen
    Zammit, Rosa-Rita
    Haire, Anna
    Sinha, Rajesh
    Simcock, Richard
    Moss, Charlotte Hannah
    Mera, Anca
    Mansi, Janine
    Karapanagiotou, Eleni
    Sawyer, Elinor
    Patel, Gargi Surendra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345